

Disseminated herpes zoster

Kaoutar Laamari¹, Hanane Baybay², Imane Couissi³, Zakia Douhi⁴, Sara Elloudi⁵, Fatima Zahra Mernissi⁶

¹⁻⁶ Department of Dermatology and Venerology, University Hospital Hassan II, Fez, Morocco

Abstract

Herpes zoster is a clinical syndrome which usually presents with a localized, vesicular rash in a dermatomal distribution. Cutaneous dissemination can occur in immunocompromised patients. Herein, we report a case of disseminated cutaneous herpes zoster in an immunocompromised patient

Keywords: herpes zoster, syndrome, localized, dermatomal

Introduction

Herpes zoster is a clinical syndrome which usually presents with a localized, vesicular rash in a dermatomal distribution. In immunocompromised patients, it may take on an unusual, often ulcerative, necrotic appearance. It can also spread to the skin or visceral level or be prolonged or recurrent. The risk of superinfection is also increased in this area [1].

Herein, we report a case of disseminated cutaneous herpes zoster in an immunocompromised patient.

Case report

A 75-year-old man adult developed a cluster of vesicular lesions over at the occipital level, which spread to involve the nape the upper part of the hemithorax and the back with associated burning-like pain over the affected area. Patient had a history of lymphoma under chemotherapy. On examination, we have found multiple vesicles surmounted haemorrhagic crusts and melliceric with some erosions. The patient was suffering a lot of pain that did not respond to paracemol.

We also found that the patient had ichthyosiform scales at the lower limbs and it was probably a paraneoplastic ichthyosis

The diagnosis of multimeric herpes zoster was made and the patient was treated by valacyclovir VI 1g 3 times per day associated with an analgesic type of tramadol and vitamin therapy with good evolution.

Discussion

Classic herpes zoster (HZ) presents as a dermatomal eruption of painful erythematous papules that evolve into grouped vesicles or bullae. Thereafter, the lesions can become pustular or hemorrhagic. Although the diagnosis most often is made clinically, confirmatory techniques for diagnosis include viral culture, direct fluorescent antibody testing, or polymerase chain reaction (PCR) assay [2, 3].

Disseminated herpes zoster is usually defined as a generalized eruption of more than 10-12 extradermatomal vesicles occurring 7-14 days after the onset of classic dermatomal herpes zoster. Typically, it is clinically indistinguishable from varicella (chickenpox). Dissemination occurs in approximately 2% of zoster cases in the general population but has been observed in as many as 35% of patients who are hospitalized or immunocompromised.

Initial cranial nerve involvement was most common which is not the case of our patient [4, 5].

The main risk factor for HZ is advanced age, most commonly affecting elderly patients.

Similarly affected are immunocompromised individuals, including those with one of the following conditions: use of antineoplastic and immunosuppressive medications, cancer, HIV infection, immunologic disorders, and organ transplants [6] millary tuberculosis (TB) was also added to the immunosuppressive conditions, as it has been associated with T cell deficiency [7].

So we need to be careful with these patients because, we can have some atypical presentation that was described like painless HZ lesions in a nondermatomal pattern in a patient who also had AIDS., and interestingly, multiple reports have found that patients with a severe but painless rash are less likely to have experienced a viral prodrome consisting of hyperesthesia, paresthesia, or pruritus. This observation suggests that lack of a prodrome is possible in immunocompromised patients [8, 9, 10, 11].

But, like you know that reactivation of the varicella-zoster virus (VZV) causes dermatomal herpes zoster (HZ) and more rarely severe disseminated HZ including diffuse rash, encephalitis, hepatitis, and pneumonitis. The disseminated HZ has been described in immunocompetent patient but further research is needed to identify the exact mechanisms [12, 13].



Fig 1 A, B: multiple vesicles surmounted haemorrhagic crusts and melliceric with some erosions

As the cutaneous dissemination of HZ is thought to be via viremia, patients are often treated with intravenous antivirals to prevent cutaneous and visceral dissemination. Overall, cutaneous dissemination of HZ in the patients reviewed was associated with low morbidity and mortality.

Conclusion

Herpes zoster is a clinical syndrome that is not difficult to diagnosis, despite the low morbidity and mortality, we need to be careful with immunocompromised patient but also for possible complications.

References

1. Daniel J, Lewis BA. Atypical Disseminated Herpes Zoster: Management Guidelines in Immunocompromised Patient by *Cutis*. 2017; 100(5):321-324.
2. McCrary ML, Severson J, Tyring SK. Varicella zoster virus. *J Am Acad Dermatol*, 1999; 41:1-16.
3. Nagasako EM, Johnson RW, Griffin DR, *et al*. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. *J Am Acad Dermatol*, 2002; 46:834-839.
4. Blein C, Gavazzi G, Paccalin M, Baptiste C, Berrut G, Vainchtock A, *et al*. Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France. *BMC Infect Dis*. 2015 ; 15(1):350. [Medline].
5. Whitley RJ, Gnann JW, Jr., Hinthorn D, *et al*. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. *J Infect Dis*, 1992; 165:450-5 [PubMed] [Google Scholar]
6. Joesoef RM, Harpaz R, Leung J, Bialek SR. Chronic medical conditions as risk factors for herpes zoster. *Mayo Clin Proc*, 2012; 87:961-7. [PMC free article] [PubMed] [Google Scholar]
7. Davoudi S, Rasoolinegad M, Younesian M, *et al*. CD4+ cell counts in patients with different clinical manifestations of tuberculosis. *Braz J Infect Dis*, 2008; 12:483-6 [PubMed] [Google Scholar]
8. Gnann JW Jr. Varicella-zoster virus: atypical presentations and unusual complications. *J Infect Dis*. 2002; 186(suppl 1):S91-S98
9. Blankenship W, Herchline T, Hockley A. Asymptomatic vesicles in a patient with the acquired immunodeficiency syndrome. disseminated varicella-zoster virus (VZV) infection. *Arch Dermatol*, 1994; 130:1193-1196.
10. Nagasako EM, Johnson RW, Griffin DR, *et al*. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. *J Am Acad Dermatol*, 2002; 46:834-839
11. Katz J, Cooper EM, Walther RR, *et al*. Acute pain in herpes zoster and its impact on health-related quality of life. *Clin Infect Dis*, 2004; 39:342-348.
12. Koc Y, Miller KB, Schenkein DP, *et al*. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. *Biol Blood Marrow Transplant*, 2000; 6:44-9 [PubMed] [Google Scholar]
13. Bezold G, Lange M, Pillekamp H, Peter RU. Varicella zoster viraemia during herpes zoster is not associated

with neoplasia. *J Eur Acad Dermatol Venereol*, 2002; 16:357-60 [PubMed] [Google Scholar]